Price (delayed)
$0.8201
Market cap
$11.48M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$6.32
Enterprise value
$7.56M
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors and viruses. ...
Highlights
The EPS has surged by 58% year-on-year and by 46% since the previous quarter
MBRX's net income is up by 28% since the previous quarter and by 27% year-on-year
MBRX's quick ratio has dropped by 77% year-on-year and by 52% since the previous quarter
The company's equity has shrunk by 77% YoY and by 20% QoQ
Key stats
What are the main financial stats of MBRX
MarketValuationsEarnings
Shares outstanding
14M
Market cap
$11.48M
Enterprise value
$7.56M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.41
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$26.64M
Net income
-$21.76M
EBIT
-$21.76M
EBITDA
-$21.64M
Free cash flow
-$23.88M
Per shareBalance sheetLiquidity
EPS
-$6.32
EPS diluted
-$6.32
Free cash flow per share
-$6.93
Book value per share
$1.99
Revenue per share
$0
TBVPS
$1.68
Total assets
$16.93M
Total liabilities
$10.95M
Debt
$358,000
Equity
$5.98M
Working capital
-$165,000
Debt to equity
0.06
Current ratio
0.97
Quick ratio
0.8
Net debt/EBITDA
0.18
MarginsEfficiencyDividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-90%
Return on equity
-165%
Return on invested capital
N/A
Return on capital employed
-188.2%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MBRX stock price
How has the Moleculin Biotech stock price performed over time
Intraday
-5.59%
1 week
-21.14%
1 month
-24.06%
1 year
-84.53%
YTD
-51.76%
QTD
-15.77%
Financial performance
How have Moleculin Biotech's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$26.64M
Net income
-$21.76M
Gross margin
N/A
Net margin
N/A
MBRX financials
MBRX's net income is up by 28% since the previous quarter and by 27% year-on-year
MBRX's operating income is up by 10% YoY and by 8% from the previous quarter
Growth
What is Moleculin Biotech's growth rate over time
MBRX growth chart
Valuation
What is Moleculin Biotech stock price valuation
P/E
N/A
P/B
0.41
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Price to earnings (P/E)
The EPS has surged by 58% year-on-year and by 46% since the previous quarter
Price to book (P/B)
The company's equity has shrunk by 77% YoY and by 20% QoQ
MBRX's price to book (P/B) is 66% lower than its 5-year quarterly average of 1.2 and 41% lower than its last 4 quarters average of 0.7
Price to sales (P/S)
Efficiency
How efficient is Moleculin Biotech business performance
The company's return on equity has shrunk by 104% YoY
Moleculin Biotech's return on assets has decreased by 33% YoY but it has increased by 12% QoQ
Dividends
What is MBRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MBRX.
Financial health
How did Moleculin Biotech financials performed over time
Assets vs liabilities
Moleculin Biotech's total assets is 55% higher than its total liabilities
MBRX's quick ratio has dropped by 77% year-on-year and by 52% since the previous quarter
The current ratio has plunged by 75% YoY and by 53% from the previous quarter
Debt vs equity
MBRX's debt is 94% smaller than its equity
The debt to equity has soared by 200% YoY and by 20% from the previous quarter
The company's equity has shrunk by 77% YoY and by 20% QoQ
Balance sheet
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from 
and Sharadar.